Noninvasive Precision Screening of Prostate Cancer by Urinary Multimarker Sensor and Artificial Intelligence Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Park, S. | - |
dc.contributor.author | Jeong, I.G. | - |
dc.contributor.author | Song, S.H. | - |
dc.contributor.author | Jeong, Y. | - |
dc.contributor.author | Kim, C.-S. | - |
dc.contributor.author | Lee, K.H. | - |
dc.date.accessioned | 2021-12-03T05:41:45Z | - |
dc.date.available | 2021-12-03T05:41:45Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2021-03-23 | - |
dc.identifier.issn | 1936-0851 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129051 | - |
dc.description.abstract | Screening for prostate cancer relies on the serum prostate-specific antigen test, which provides a high rate of false positives (80%). This results in a large number of unnecessary biopsies and subsequent overtreatment. Considering the frequency of the test, there is a critical unmet need of precision screening for prostate cancer. Here, we introduced a urinary multimarker biosensor with a capacity to learn to achieve this goal. The correlation of clinical state with the sensing signals from urinary multimarkers was analyzed by two common machine learning algorithms. As the number of biomarkers was increased, both algorithms provided a monotonic increase in screening performance. Under the best combination of biomarkers, the machine learning algorithms screened prostate cancer patients with more than 99% accuracy using 76 urine specimens. Urinary multimarker biosensor leveraged by machine learning analysis can be an important strategy of precision screening for cancers using a drop of bodily fluid. © | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | American Chemical Society | - |
dc.title | Noninvasive Precision Screening of Prostate Cancer by Urinary Multimarker Sensor and Artificial Intelligence Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, K.H. | - |
dc.identifier.doi | 10.1021/acsnano.0c06946 | - |
dc.identifier.scopusid | 2-s2.0-85097732503 | - |
dc.identifier.wosid | 000634569100028 | - |
dc.identifier.bibliographicCitation | ACS Nano, v.15, no.3, pp.4054 - 4065 | - |
dc.relation.isPartOf | ACS Nano | - |
dc.citation.title | ACS Nano | - |
dc.citation.volume | 15 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 4054 | - |
dc.citation.endPage | 4065 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Physical | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | IMMUNOASSAY | - |
dc.subject.keywordPlus | TECHNOLOGY | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordPlus | PLATFORM | - |
dc.subject.keywordPlus | BIOPSY | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordAuthor | artificial intelligence | - |
dc.subject.keywordAuthor | cancer screening | - |
dc.subject.keywordAuthor | multimarker | - |
dc.subject.keywordAuthor | prostate cancer | - |
dc.subject.keywordAuthor | urine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.